February 4, 2014
Boston, MA
Did you just receive a Paragraph IV notice letter? Are you expecting one in the near future? Do you have a patented drug product that you plan to put before the FDA for approval and ultimately list in the Orange Book?
One patent is often the key protection for a multi-billion dollar pharmaceutical investment. Thus, the decisions you make today can make or break your product’s future profitability. Finnegan attorneys will share their many years of experience strategically defending clients in cases arising from the filing of Abbreviated New Drug Applications and prosecuting Orange Book listed patents. They will discuss current Federal Circuit case law, critical issues to consider in preparing for an ANDA case, and the potential impact new AIA proceedings may have on ANDA litigation. Topics to be discussed include:
Please join our Finnegan attorneys as they share their years of experience successfully representing clients in cases arising from the filing of ANDAs and prosecuting Orange Book listed patents directed to the following drugs: Evista®, Zyprexa®, Comtan®, Crestor®, Cymbalta®, Gemzar®, Prozac®, Stalevo®, Lovenox®, Pulmicort®, Respules®, Taxotere®, Eloxatin®, Lantus®, Crestor®, Allegra®, as well as Apidra®, Differin 0.3% Gel®, Rilutek®, Ramipril®, Duexis®, Viracept®, Rimonabant®, Lorcaserin®, HMPL 0004®, and BG-12®.
There is no charge to attend. Due to space limitations, please register early.
Mary K. Ferguson, Ph.D.
Tom Irving
Howard W. Levine
Charles E. Lipsey
Sanya Sukduang
Tuesday, February 4, 2014
Finnegan
Two Seaport Lane
Boston, MA 02210
9:30 - 10:00 a.m.
Registration and Breakfast
10:00 - 11:50 a.m.
Workshop
11:50 a.m. - 12:50 p.m.
Working Lunch
12:50 - 4:00 p.m.
Workshop
Conference
2nd Annual Forum on IP, Funding and Tech Strategies for Novel Therapeutic Modalities
March 20, 2024
Boston
WTR Live: Brand Strategy Summit Europe 2024
March 12-13, 2024
London
Conference
2024 LES Thailand Annual Conference: Cutting-Edge Strategies for Global IP Licensing
February 16, 2024
Bangkok
At the PTAB Blog
February 15, 2024
Prosecution First Blog
Safe Harbor Protection: Acadia Pharms., Inc. v. Aurobindo Pharma Ltd.
February 9, 2024
Ad Law Buzz Blog
February 1, 2024
Ad Law Buzz Blog
Natural-ish: A New Decision Underscores NAD’s Expansive Understanding of Natural Claims
January 26, 2024
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.